News

Fycompa, which was discovered and developed in the UK and Japan, was first launched globally in the UK on 12 September 2012. The production of the drug will

The company expects the process of activation, recruitment, enrolling and first dosing to take nearly 3 weeks. Cellceutix president and chief scientific officer Krishna Menon said institutions such

The two-year, $582,763 grant will be used to develop Biodel’s proprietary glucagon to deliver it as part of a bihormonal closed loop system to mitigate hypoglycemic events. Biodel

Tacrolimus, developed by Astellas, is a once daily formulation of calcineurin-inhibitor immunosuppressant tacrolimus. Astellas global transplantation therapeutic area head Roy First said there remains a large unmet treatment

Equipped with Bruker’s self-optimizing ScanAsyst Imaging Mode and PeakForce TUNA module, the AFM system is designed for use in conductivity mapping as well as to characterize other difficult

The results of the 60-day, placebo-controlled, single-ascending dose trial demonstrated that the single doses of VRS-317 were safe and well tolerated while adverse events that were considered drug

Extracted from senna leaves and pods, Sennosides are used as laxatives in traditional and modern medicine preparations. Alchem International president Raman Mehta said expansion of the company’s facility

RXI-109 is being developed to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. RXi president and

Valeant made $62.5m upfront payment for US rights and available inventories for Visudyne and another $50m for rights to non-US royalties on Visudyne sales. QLT is also entitled